LEADER 03437nam  22006975  450 
001 9910298268203321
005 20200703172544.0
010   $a1-4939-2724-8
024 7 $a10.1007/978-1-4939-2724-1
035   $a(CKB)3710000000436712
035   $a(EBL)2094766
035   $a(SSID)ssj0001524947
035   $a(PQKBManifestationID)11979183
035   $a(PQKBTitleCode)TC0001524947
035   $a(PQKBWorkID)11485422
035   $a(PQKB)11373386
035   $a(DE-He213)978-1-4939-2724-1
035   $a(MiAaPQ)EBC2094766
035   $a(PPN)186395876
035   $a(EXLCZ)993710000000436712
100   $a20150624d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aInflammation and Lung Cancer /$fedited by Steven M. Dubinett
205   $a1st ed. 2015.
210  1$aNew York, NY :$cSpringer New York :$cImprint: Springer,$d2015.
215   $a1 online resource (215 p.)
300   $aDescription based upon print version of record.
311   $a1-4939-2723-X 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aInflammation and Lung Cancer: The relationship to COPD -- Inflammation and Lung Cancer: The role of EMT -- Inflammation and Lung Cancer: Molecular pathology -- Inflammation and Lung Cancer: Prevention -- Inflammation and Lung Cancer: The Link to Angiogenesis -- Inflammation and Lung Cancer: Eicosanoids -- Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy.
330   $aThis volume  presents aspects of the inflammatory tumor microenvironment (TME) and its many roles in tumor progression and metastasis, including creation of a hypoxic environment, increased angiogenesis and invasion, changes in expression of microRNAs (miRNAs), and an increase in a stem cell phenotype. The volume also covers the mechanisms of inflammatory mediators. Chronic overexpression of inflammatory mediators in the TME, as seen in smokers and patients with non-small cell lung cancer (NSCLC), can also lead to increased tumor initiation, progression, invasion, and metastasis. The volume will provide a comprehensive perspective of the latest findings and summaries of progress made regarding inflammation and its connection to lung cancer.
606   $aCancer$xResearch
606   $aPathology
606   $aMedical microbiology
606   $aImmunology
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
606   $aPathology$3https://scigraph.springernature.com/ontologies/product-market-codes/H4800X
606   $aMedical Microbiology$3https://scigraph.springernature.com/ontologies/product-market-codes/B16003
606   $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000
615  0$aCancer$xResearch.
615  0$aPathology.
615  0$aMedical microbiology.
615  0$aImmunology.
615 14$aCancer Research.
615 24$aPathology.
615 24$aMedical Microbiology.
615 24$aImmunology.
676   $a610
676   $a614.5999
676   $a616.07
676   $a616.079
676   $a616.9041
702   $aDubinett$b Steven M$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910298268203321
996   $aInflammation and Lung Cancer$92539264
997   $aUNINA